No FDA-approved hantavirus vaccine is expected in 2026, as no candidates have reached Phase 3 trials and most mRNA or DNA platforms targeting orthohantavirus glycoproteins remain in preclinical animal models or early Phase 1 safety testing. A May 2026 Andes virus outbreak on a cruise ship prompted modest funding increases and surveillance attention from agencies like WHO and CDC, yet low disease incidence continues to constrain large-scale efficacy studies. Full licensure typically requires multi-year human trials with clear endpoints for hantavirus pulmonary syndrome or hemorrhagic fever with renal syndrome, making accelerated approval unlikely absent unprecedented regulatory shifts. Trader consensus at 94.5% reflects these established development barriers.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% 確率
$129,673 Vol.
$129,673 Vol.
2026/12/31
6% 確率
$129,673 Vol.
$129,673 Vol.
2026/12/31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No FDA-approved hantavirus vaccine is expected in 2026, as no candidates have reached Phase 3 trials and most mRNA or DNA platforms targeting orthohantavirus glycoproteins remain in preclinical animal models or early Phase 1 safety testing. A May 2026 Andes virus outbreak on a cruise ship prompted modest funding increases and surveillance attention from agencies like WHO and CDC, yet low disease incidence continues to constrain large-scale efficacy studies. Full licensure typically requires multi-year human trials with clear endpoints for hantavirus pulmonary syndrome or hemorrhagic fever with renal syndrome, making accelerated approval unlikely absent unprecedented regulatory shifts. Trader consensus at 94.5% reflects these established development barriers.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
マーケット開始日： May 4, 2026, 10:39 AM ET
音量
$129,673終了日
2026/12/31マーケット開始日
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No FDA-approved hantavirus vaccine is expected in 2026, as no candidates have reached Phase 3 trials and most mRNA or DNA platforms targeting orthohantavirus glycoproteins remain in preclinical animal models or early Phase 1 safety testing. A May 2026 Andes virus outbreak on a cruise ship prompted modest funding increases and surveillance attention from agencies like WHO and CDC, yet low disease incidence continues to constrain large-scale efficacy studies. Full licensure typically requires multi-year human trials with clear endpoints for hantavirus pulmonary syndrome or hemorrhagic fever with renal syndrome, making accelerated approval unlikely absent unprecedented regulatory shifts. Trader consensus at 94.5% reflects these established development barriers.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
音量
$129,673終了日
2026/12/31マーケット開始日
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No FDA-approved hantavirus vaccine is expected in 2026, as no candidates have reached Phase 3 trials and most mRNA or DNA platforms targeting orthohantavirus glycoproteins remain in preclinical animal models or early Phase 1 safety testing. A May 2026 Andes virus outbreak on a cruise ship prompted modest funding increases and surveillance attention from agencies like WHO and CDC, yet low disease incidence continues to constrain large-scale efficacy studies. Full licensure typically requires multi-year human trials with clear endpoints for hantavirus pulmonary syndrome or hemorrhagic fever with renal syndrome, making accelerated approval unlikely absent unprecedented regulatory shifts. Trader consensus at 94.5% reflects these established development barriers.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問